Glutamatergic transmission in schizophrenia: from basic research to clinical practice

PURPOSE OF REVIEWThe past 20 years have seen the glutamatergic hypothesis go from theory to phase III trials of novel mechanism antipsychotics. RECENT FINDINGSWe review the recent literature on glutamatergic theory, covering assessment and genetic studies, as well as drug development in animals and...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Current opinion in psychiatry 2012-03, Vol.25 (2), p.96-102
Hauptverfasser:	Kantrowitz, Joshua, Javitt, Daniel C
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antipsychotic Agents - therapeutic use Biomarkers - metabolism Clinical medicine Clinical Trials as Topic Genetics Glutamic Acid - genetics Glutamic Acid - metabolism Humans Mental health care Rats Receptors, N-Methyl-D-Aspartate - antagonists & inhibitors Schizophrenia Schizophrenia - diagnosis Schizophrenia - drug therapy Schizophrenia - genetics Schizophrenia - metabolism Schizophrenia - physiopathology Thalamus - metabolism Tranquilizers
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	PURPOSE OF REVIEWThe past 20 years have seen the glutamatergic hypothesis go from theory to phase III trials of novel mechanism antipsychotics. RECENT FINDINGSWe review the recent literature on glutamatergic theory, covering assessment and genetic studies, as well as drug development in animals and humans. SUMMARYAlthough evidence continues to accumulate in support of glutamate hypotheses, further research continues to be required and interactions with other key systems need to be explored.
ISSN:	0951-7367 1473-6578
DOI:	10.1097/YCO.0b013e32835035b2